Quote this publication Share Print

OMNITROPE

-
Opinions on drugs - Posted on Apr 02 2013

Reason for request

Renouvellement d'inscription

-


Actual benefit

Modéré

The actual benefit of OMNITROPE in adults with GH deficiency remains moderate.

Faible

The actual benefit of OMNITROPE in children born small for gestational age with a birth weight and/or length < -2 SD, who have failed to show catch-up growth (growth velocity < 0 SD during the last year) by 4 years of age or later and whose growth retardation (current height) is below or equal to -3 SD and the adjusted parental height < -1 SD remains low.

Important

The actual benefit of OMNITROPE in children with GH deficiency remains substantial.

The actual benefit of OMNITROPE in Turner syndrome remains substantial.

The actual benefit of OMNITROPE in chronic renal impairment remains substantial.


Contact Us

Évaluation des médicaments

See also